Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Filter bei nächster Suche beibehalten
journalStr:"Cancers"
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?lookfor=%22Daratumumab%22&type=Subject&filter%5B%5D=journalStr%3A%22Cancers%22
/vufind/Search/Results?lookfor=%22Daratumumab%22&type=Subject&filter%5B%5D=journalStr%3A%22Cancers%22
Search /vufind/Search2/Results?lookfor=%22Daratumumab%22&type=Subject&filter%5B%5D=journalStr%3A%22Cancers%22
PubPharm (19)
1
Does the Simultaneous Introduction of Several Pharmaceuticals in the Post-Lenalidomide Era Translate to Better Outcomes in Relapse Refractory Multiple Myeloma? Findings from the Real-World Innovation in Multiple Myeloma (REAL IMM) Study
enthalten in:
Cancers
| 2023
von
Petrakis, I.
|
Kontogiorgis, C.
|
Nena, E.
| +9
Wird geladen...
2
Efficacy and Safety of Daratumumab, Pomalidomide, and Dexamethasone (DPd) Compared to Daratumumab, Bortezomib, and Dexamethasone (DVd) in Daratumumab-Naïve Relapsed Multiple Myeloma
enthalten in:
Cancers
| 2023
von
Afrough, A.
|
Atrash, S.
|
Paul, B.
| +7
Wird geladen...
3
Daratumumab, Bortezomib, and Dexamethasone for Treatment of Patients with Relapsed or Refractory Multiple Myeloma and Severe Renal Impairment : Results from the Phase 2 GMMG-DANTE Trial
enthalten in:
Cancers
| 2023
von
Leypoldt, L.
|
Gavriatopoulou, M.
|
Besemer, B.
| +12
Wird geladen...
4
Daratumumab, Bortezomib, and Dexamethasone for treatment of patients with relapsed or refractory multiple myeloma and severe renal impairment : results from the phase 2 GMMG-DANTE trial
enthalten in:
Cancers
| 2023
von
Leypoldt, L.
|
Gavriatopoulou, M.
|
Besemer, B.
| +12
Wird geladen...
5
Efficacy and Safety of Daratumumab, Pomalidomide, and Dexamethasone (DPd) Compared to Daratumumab, Bortezomib, and Dexamethasone (DVd) in Daratumumab–Naïve Relapsed Multiple Myeloma
in:
Cancers
| 2023
von
Aimaz Afrough
|
Shebli Atrash
|
Barry Paul
| +7
Wird geladen...
6
Daratumumab, Bortezomib, and Dexamethasone for Treatment of Patients with Relapsed or Refractory Multiple Myeloma and Severe Renal Impairment: Results from the Phase 2 GMMG-DANTE Trial
in:
Cancers
| 2023
von
Lisa B. Leypoldt
|
Maria Gavriatopoulou
|
Britta Besemer
| +12
Wird geladen...
7
Does the Simultaneous Introduction of Several Pharmaceuticals in the Post-Lenalidomide Era Translate to Better Outcomes in Relapse Refractory Multiple Myeloma? Findings from the Real-World Innovation in Multiple Myeloma (REAL IMM) Study
in:
Cancers
| 2023
von
Ioannis Petrakis
|
Christos Kontogiorgis
|
Evangelia Nena
| +9
Wird geladen...
8
Daratumumab Improves Bone Turnover in Relapsed/Refractory Multiple Myeloma; Phase 2 Study "REBUILD"
enthalten in:
Cancers
| 2022
von
Terpos, E.
|
Ntanasis-Stathopoulos, I.
|
Kastritis, E.
| +13
Wird geladen...
9
A Systematic Review of Cost-Effectiveness Analyses of Novel Agents in the Treatment of Multiple Myeloma
enthalten in:
Cancers
| 2021
von
Seefat, M.
|
Cucchi, D.
|
Dirven, S.
| +3
Wird geladen...
10
A Mathematical Modeling Approach for Targeted Radionuclide and Chimeric Antigen Receptor T Cell Combination Therapy
enthalten in:
Cancers
| 2021
von
Adhikarla, V.
|
Awuah, D.
|
Brummer, A.
| +8
Wird geladen...
1
2
Nächster »
[2]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Clinical Studies
Patente
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Ihre gewählten Filter
Filter bei nächster Suche beibehalten
Filter aufheben
Zeitschrift: Cancers
Medienart
19
Aufsätze
19
E-Artikel
19
E-Ressourcen
Zeitschriftentitel
Cancers
Thema
17
daratumumab
17
multiple myeloma
12
Journal Article
6
Neoplasms. Tumors. Oncology. Including cancer a...
5
carfilzomib
5
immunotherapy
4
CD38
4
clinical trial
4
pomalidomide
3
PD-L1
3
checkpoint inhibitor
3
hemodialysis
3
ixazomib
3
relapsed/refractory
3
renal impairment
2
DPd
2
DVd
2
Daratumumab naïve
2
RRMM
2
Review
Alle anzeigen ...
weniger ...
Erscheinungszeitraum
7
2023
1
2022
9
2021
2
2020
Erscheinungsjahr(e)
Von:
Bis:
Sprache
19
Englisch
Haven't found what you're looking for?
Wird geladen...